Abstract
Neurodegenerative disorders are a group of disorders that affect elderly, with a small portion being hereditary in nature. Both genetic and non-genetic factors contribute in the development of this array of diseases. With the majority of cases being sporadic, the search for authenticated therapeutic option is demanding. Recently, CRISPR/Cas9-based therapy become potential to treat several human diseases, especially neurodegenerative such as Parkinson disease (PD), Huntington disease (HD), Alzheimer disease (AD), and amyotrophic lateral sclerosis (ALS). In this minireview, we highlight how CRISPR/Cas9 become in action to treat these life-threatening diseases and widen the view to the future perspectives and limitations of this technology towards other complicated diseases such as frontotemporal dementia (FTD) and the spinocerebellar ataxias (SCA).